Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat |
| |
Authors: | Z. Speiser A. Mayk L. Litinetsky T. Fine A. Nyska E. Blaugrund S. Cohen |
| |
Affiliation: | (1) Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel;(2) R&D Division, Teva Pharmaceutical Industries Ltd., Netanya, Israel;(3) School of Continuing Education, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel |
| |
Abstract: | Summary. The neuroprotective effects of intravenous rasagiline were investigated in a rat model of stroke. Middle cerebral artery (MCA) occlusion was performed in male rats and the short- (neurological severity score [NSS], infarct size), intermediate- (cognition) and long-term (necrotic area) effects were assessed. A bolus (3 mg/kg) of rasagiline followed by a 3-h infusion (3 mg/kg/h), initiated immediately after MCA occlusion, reduced infarct size by 48.6% and NSS by 32.7% relative to saline treatment. Cognitive function, tested in a water maze 2–3 weeks after occlusion, also significantly improved compared with saline-treated controls. Necrotic brain area was 35–50% smaller with rasagiline than with saline following a single bolus dose. The single bolus rasagiline dose was as effective as a rasagiline bolus followed by rasagiline infusion in short-term outcomes. The neuroprotective effect of rasagiline was fully reproducible when administered at 2 h following occlusion but not after 4 h. |
| |
Keywords: | : Cognition histopathological outcome infarct volume middle cerebral artery occlusion neurological severity score |
本文献已被 PubMed SpringerLink 等数据库收录! |
|